January 25 2016 by Ray Sahelian, M.D.
A search on Medline in January 2016 did not show any studies published in the past few years with this herbal product.
Flavoxine is a blend of two plant extracts, a proprietary extract of Phellodendron amurense and a patented extract of orange peel containing polymethoxylated flavones.
Carlsbad, CA - 2006 - Next Pharmaceuticals
announced the results of a clinical trial on their new-patented heart health
ingredient Flavoxine. The double-blind placebo-controlled clinical trial with 80
subjects indicated that Flavoxine increased HDL-cholesterol, the so-called
“good” cholesterol while reducing LDL-cholesterol, the so-called “bad”
cholesterol, and triglycerides. In addition, Flavoxine reduced C-reactive
protein (CRP), an indicator of inflammation, and it lowered blood pressure and
fasting blood glucose in the overweight individuals with elevated cholesterol
“Flavoxine is the result of Next Pharmaceuticals devoting many years to finding
a natural formula for heart health” said Bob Garrison, President and CEO of Next
Pharmaceuticals. “We believe Flavoxine will be a natural ingredient for
maintaining a healthy heart. The active compounds from the plants used have been
studied extensively and therefore Flavoxine does not have the risks frequently
associated with new synthetic compounds.“
The principal investigator for the trial was Dr. Julius E. Oben, Head of the Department of Biochemistry, University of Yaounde in Cameroon. Next Pharmaceuticals is seeking to replicate the trial in the U.S., through a joint effort with an academic institution under a National Institutes of Health grant.
About Next Pharmaceuticals
Next Pharmaceuticals was founded in 1997 with the purpose of developing new, patented, natural ingredients for healthy living products in the dietary supplement, food and beverage industries. Next Pharmaceuticals has developed six patented plant extracts that have significantly expanded the choices for self-care products, while providing large consumer brands with powerful product differentiation. Through the application of pharmaceutical technologies to natural botanical materials, including citrus fruits, Next Pharmaceuticals has developed Relora for relaxation and stress-related appetite control, Nexrutine for inflammation, Sedito® for better quality of sleep, Flavoxine & Citri-Z for heart health, Citrofen for pain, and Chromulin for carbohydrate and lipid metabolism. These ingredients are available for licensing to qualified companies.